A new family of thirteen phosphoramidate prodrugs (ProTides) of different 6-substituted-5-fluorouridine nucleoside analogues were synthesized and evaluated as potential anticancer agents. In addition, antiviral activity against Chikungunya (CHIKV) virus was evaluated using a cytopathic effect inhibition assay. Although a carboxypeptidase Y assay supported a putative mechanism of activation of ProTides built on 5-fluorouridine with such C6-modifications, the Hint docking studies revealed a compromised substrate-activity for the Hint phosphoramidase-type enzyme that is likely responsible for phosphoramidate bioactivation through P-N bond cleavage and free nucleoside 5'-monophosphate delivery. Our observations may support and explain to some extent the poor in vitro biological activity generally demonstrated by the series of 6-substituted-5-fluorouridine phosphoramidates (ProTides) and will be of guidance for the design of novel phosphoramidate prodrugs.
Introduction
Antimetabolites such as nucleoside analogues (NAs) play a crucial role in the clinical treatment of patients with cancer and viral infections. [1] [2] [3] Nucleoside analogues are chemically-modified synthetic compounds that have been developed with the aim to closely mimic their natural counterparts. Hence, they have a good chance to be able to be taken-up by cells, metabolized and incorporated into nucleic acids to subsequently inhibit cellular division and/or viral replication. At the molecular level, the biological effect of NAs is usually exerted following their metabolic conversion into corresponding 5'-mono-, di-and tri-phosphate forms. In addition to their incorporation into newly synthesized DNA or RNA, NAs can target and inhibit intracellular enzymes like for example viral or human polymerases, ribonucleotide reductase 4 (RNR), thymidylate synthase 5 (TS) or orotidine-5'-monophosphate decarboxylase 6a,b (ODCase). All these enzymes are involved either in the DNA or RNA synthesis, DNA repair or de novo pyrimidine nucleotide synthesis. Because de novo synthesis of pyrimidine nucleotides is upregulated during abnormal cell growth or during the replication of cells, when the demand for pyrimidine nucleotides is high, the ODCase can be considered as one of the potential anticancer targets. 7 In fact, in the last decades a significant interest has been given to ODCase as a drug target for a number of modified nucleos(t)ide analogues, in particular C6-substituted UMP derivatives also in the antiviral and antimalarial arena. [7] [8] [9] [10] This is due to a pivotal role that ODCase plays in the de novo synthesis of pyrimidine nucleotides such as uridine- nucleo(s)(t)ide deaminases, purine/pyrimidine nucleoside phosphorylase…). 18 To overcome these limitations, and thus improving their effectiveness, several prodrug approaches have been developed and reviewed over the last years. Notably, phosphate
and phosphonate prodrugs such as phosphodiesters (HepDirect, CycloSal, SATE) or phosporamidates in which a nucleoside analogue is linked to the prodrug entity by either a phosphorus-oxygen or a phosphorus-nitrogen bond, respectively, have been extensively studied. [19] [20] [21] One of the prominent strategies applied in the modulation of the activity of many nucleoside analogues and potentially overcoming the NA limitations accounting on both innate and acquired resistance of cancer cells to nucleoside analogues, is the ProTide technology pioneered by McGuigan and colleagues. 22 Designed to mask the negative charges in a "monophosphate moiety" of a ProTide template, the ProTide approach introduces an amino acid ester and aryloxy entities as two lipophilic and biolabile groups linked to the phosphate part of the molecule. These two groups increase membrane permeability thereby circumventing the need for nucleoside-transporters and after their intracellular metabolism delivering a nucleoside monophosphate form suitable for further phosphorylation and exertion of its eventual biological activity. [28] [29] [30] and anticancer agents such as for example 5-fluoro-2'-deoxyuridine (FdUrd), 31 and gemcitabine. 32 As part of our anticancer program and driven by our continuous interests in the discovery of novel anticancer agents we decided to apply the ProTide approach also to 6-substituted-5-fluorouridine
analogues. In addition, a new class of 2'-fluoro-6-substituted uridine derivatives reported in the literature 7 as potential inhibitors of ODCase revealed the lack of cellular anticancer activities most likely due to their poor activation to the corresponding 5'-monophosphate forms. Herein, we report the ProTide technology approach employed to 6-substituted-5-fluorouridine analogues (5-8) to design novel nucleoside phosphoramidates (25-37) as potential anticancer agents. These compounds were prepared with the aim to improve cellular uptake of their parent nucleoside analogues and intracellular delivery of their corresponding monophosphate forms. All compounds were preliminary tested for their IC50 activity in a panel of cancer cell lines including tumor cell lines of hematopoietic origin as these cell lines were found to be strongly inhibited by 6-substituted-5-fluorouridine analogues. 16 Figure 3. Examples of antiviral and anticancer phosporamidate-type prodrugs.
Chemistry
The 6-modified nucleosides 5-8 were prepared according to previously reported methods 16 starting from a two-steps full protection of 5-fluorouridine (17) to
give an intermediate (19) as shown in Scheme 1. The treatment of compound 19 with LDA followed by iodination with I2 led to the formation of the key nucleoside 20 that was further deprotected under acidic conditions to yield 6-I-FUR (5). In addition the iodo-derivative 20 was used to form three other 6-substituted nucleoside analogues, such as 6-azido-, 6-methyl-and 6-ethyl-FUR (21) (22) (23) . The 6-azido-derivative 21 was prepared by treating 20 with NaN3 followed by removal of its silyl and isopropylidine moieties to give compound 6. The 6-methyl (22) for RL 27 M; and for HS445 10 M). The screening of the compounds was performed on a broad variety of at least 6 different cancer cell lines to cover different metabolic properties that may exist between different types of cancer cells that may result in a different outcome of the eventual cytostatic activity of the compounds. In fact, it was observed that the cytostatic activity for some of the 6-substituted-FUR derivatives and their corresponding prodrugs (i.e. 6-I-FUR, 6-Me-FUR) may significantly differ depending on the nature of the prodrug part in the molecule and/or the nature of the tumor cell line investigated. Although the molecular basis of the observed differences are not further investigated in detail yet, the cytostatic differences may be most likely due to i) differences in drug uptake (i.e. depending on the presence and activity of different nucleoside carriers in the tumor cell membrane) and/or efflux of the drugs by the different tumor cell lines, ii) differences in levels and activity of metabolic enzymes that intracellularly convert the particular nucleotide prodrug to the parent nucleotide 5'-monophosphate, and/or iii) differences in nucleotide kinases and other enzymes that may convert the nucleoside 5'-monophosphate to the eventual 5'-triphosphate (i.e.
nucleoside 5'-monophosphate kinases and nucleoside 5'-diphosphate kinases) or to the free nucleoside or nucleobase (i.e. 5'-nucleotidases, thymidine phosphorylase). Thus, a complex interplay of a broad variety of enzymes in the particular tumor cell lines will play a determining role in the eventual cytostatic activity of the nucleotide prodrugs. It would therefore be of importance to identify these different factors to clarify and understand the underlying metabolic processes that lead to the cytostatic activity of the different ProTides.
Moreover, it has been suggested that anticancer activity of 6-substituted-FUR analogues might be exerted via inhibition of thymidylate synthase (TS). These 6-modified nucleosides would be intracellularly degraded to their nucleic bases by thymidine phosphorylase (TPase) and further transformed to the corresponding 2'-deoxynucleosides as acceptable substrates for TS. 16 In the studies of 5-fluoro-2'-deoxyuridine (FdUrd) ProTides, we have previously reported that FdUrd ProTides are completely stable in the presence of TP and uridine phosphorylase (UP). 33 In this view, it might be speculated that the ProTide promoiety introduced into the 6-substituted-5-fluorouridine analogues can potentially compromise activity of such compounds as it would prevent their conversion to 6-substituted-5-fluorouracil. Thus, a formation of 6-substituted-2'-deoxy-5-fluorouridine derivatives and their corresponding monophosphate forms would be impaired resulting in potential lack of TS inhibition.
Antiviral Activity In vitro
ODCase has been considered as a potential target for agents directed against RNA viruses such as flaviviruses, and togaviruses. 34 Numerous pyrimidine-nucleosides and their derivatives including the phosphoramidate prodrug 6-aza-uridine-5'-(ethylmethoxyalaninyl)phosphate were shown to exhibit antiviral (RNA) activity in vitro and in vivo. type enzyme. 39 In order to assess whether also 6-substituted-FUR ProTides act as a good substrate for the carboxyesterase-type enzyme and hence would be activated by the same common pathway, we performed the carboxypeptidase Y assay on one of the 6-N3-FUR ProTide, the compound 29 using a reported assay procedure. 40 Thus, 
Docking Studies: Human Hint Enzyme
The last enzymatic step required for the activation of phosphoramidate prodrugs is the cleavage of the P-N bond catalysed by the phosphoramidase-type enzyme, which belongs to the human histidine triad nucleotide-binding protein (Hint). 41 The efficiency of this step determines the eventual activity of ProTides since during this step the free nucleoside monophosphate form is intracellularly delivered. In order to investigate the potential interaction between Hint protein and metabolite 29-C and to asses its potentiality as a substrate of this enzyme, a series of molecular docking studies using the human Hint enzyme (PDB id: 1KPF) 42 were performed. The catalytic active-site is well-defined by the co-crystallized adenosine monophosphate (AMP), with the three histidine residues interacting with the substrate and Ser107, an important amino acid reported as playing a central role in catalysing the P-N bond cleavage through an acid-base catalysis, 43 making an interaction with the phosphate head. Figure 6 shows the metabolite 29-C proposed binding mode into the Hint enzyme active pocket. The nucleobase and the sugar are oriented in a different manner if compared to the AMP substrate thus forcing the phosphate moiety in a notideal position for the cleavage of the P-N bond (lacking direct interaction with Ser107). This results in a binding that could be considered as being not optimal for the proper enzyme catalytic activity. The docking results seem to suggest that 29-C and, as a consequence, the other members of this new ProTide series, might not be optimal substrates for Hint. Therefore, the release of the monophosphate form could be drastically reduced or even completely impeded. These findings are in line with previously reported data in which the Hint enzyme has been found to have a lower affinity for pyrimidine than purine derivatives 43, 44 and could potentially explain the substantial reduction or even the total lack of cytostatic activity of 6-substituted-FUR ProTides in general when compared with the parent nucleoside. 
Conclusion
In conclusion, we report on the application of the ProTide approach to 6-substituted-5-fluorouridine nucleoside analogues bearing at the C6-position of the 5-fluorouridine scaffold small substituents such as iodo, azido, methyl and ethyl with the aim to prepare potential anticancer and anti-viral agents. It is worth mentioning that during the one-pot synthesis of the 6-alkyl substituted-5-fluorouridine analogues using methyl iodide and LDA, two derivatives were formed and isolated, being the target 6-methyl-and 6-ethyl-5-fluorouridine (as a side-product), respectively. In general, in our in vitro studies, 6-substituted-5-fluorouridine ProTides revealed to be less active in comparison with the parent nucleosides. Among four different 6-substituted-5-fluorouridine ProTide series, only the 6-iodo-(27) and 6-azido-(31 and 32) compounds were equipotent to the parent nucleosides 5 and 6. The differences in and/or lack of anticancer and anti-CHIKV activity in most cases may indicate either differences in drug uptake depending on the tumor cell, differences in levels and activity of metabolic enzymes and/or poor bioactivation and thus inefficient delivery were prepared. The growth medium was aspirated from the cells and the compound dilutions were added in triplicate. Cells that were incubated with medium only were used for generating the 0% cytotoxicity data. Medium was aspirated and cells were lysed for evaluation of the ATP content using Promega's CelltiterGlo kit on day 3.
The resulting luciferase luminescence was quantified and used to calculate the CC50 using a 4-PL curve fit of the OD. was added to the sample, which was then immediately submitted to the 31 P NMR analyses (at 25 C). The spectra were recorded every 7 minutes and followed 14 hours. 31 P NMR recorded data were processed and analyzed with the Bruker Topspin 2.1 program.
Chemistry. General Procedures. Solvents and Reagents. The following anhydrous solvents were purchased from Sigma-Aldrich: dichloromethane (CH2Cl2), diethyl ether (Et2O), tetrahydrofuran (THF), dimethylformamide (DMF), and any other reagents used. Amino acid esters commercially available were purchased from Novabiochem. All reagents commercially available were used without further purification.
Thin Layer Chromatography (TLC).
Precoated aluminum backed plates (60 F254, 0.2 mm thickness, Merck) were visualized under both short-and long-wave ultraviolet light (254 and 366 nm).
Preparative TLC plates (20 cm × 20 cm, 500-2000 μm) were purchased from Merck.
Flash Column Chromatography. Flash column chromatography was carried-out using silica gel supplied by Fisher (60A, 35-70 μm). Glass columns were slurrypacked using the appropriate eluent with the sample being loaded as a concentrated solution in the same eluent or preadsorbed onto silica gel. Fractions containing the product were identified by TLC, pooled and the solvent was removed in vacuo. 
High Performance Liquid Chromatography (HPLC).

5'-O-(t-Butyldimethylsilyl)-2',3'-O-isopropylidene-5-fluoro-6-iodouridine (20). 5'-
O-(t-Butyldimethylsilyl)-2',3'-O-isopropylidene-5-fluoro-uridine
5-Fluoro
5'-O-(t-Butyldimethylsilyl)-2',3'-O-isopropylidene-5-fluoro-6-azidouridine (21).
The compound 20 (1.86 g, 3.43 mmol) dissolved in anhydrous DMF (15 mL) was treated with NaN3 (0.22 g, 3.43 mmol). The reaction mixture was stirred for 3 h in dark. After that time, the solvent was evaporated, and the residue was re-dissolved in EtOAc (30 mL), washed with brine, and dried over Na2SO4. The combined organic layers were evaporated and to afford a yellowish residue which was purified by column chromatography using DCM/MeOH (99:1) as an eluent to give compound 2 as a light-yellow solid (1.16 g, 74%). 
5-Fluoro-6-azidouridine (6) A stirred solution of 5'-O-(t-butyldimethylsilyl)-2',3'-O-
isopropylidene-5-fluoro-6-azidouridine 21 (1.10 g, 2.18 mmol) in water (10 mL) was treated with 50% aqueous (10 mL) at 0C, brought to room temperature, and stirred for an additional 2 h in dark. The reaction mixture was concentrated under vacuum and was purified by column chromatography with a gradient of MeOH in DCM (6% to 12%) to give a product as a yellowish solid (0.56 g, 85%). 1 
General Method for the Preparation of phosphorochloridates (24)
. 45 Anhydrous triethylamine (2.0 mol eq.) was added dropwise at -78 ºC to a stirred solution of the appropriate aryl dichlorophosphate (1.0 mol eq.) and an appropriate amino acid ester (1.0 mol eq.) in anhydrous DCM under argon atmosphere. Following the addition, the reaction mixture was allowed to slowly warm to room temperature and stirred for 1-2 hours. A formation of a desired compound was monitored by 31 P NMR. After the reaction was completed, the solvent was evaporated under reduced pressure and the resulting residue was re-dissolved in anhydrous Et2O and filtered. The filtrate was reduced to dryness to give a crude product as an oil, which was in some cases used without further purification in the next step. Most of aryl phosphorochloridates, in particular those obtained from the amino acid tosylate salt were purified by flash column chromatography using EtOAc/Hexane (7:3) as an eluent.
General method for the preparation of phosphoramidates.
To a stirring solution of nucleoside analogue (1.0 mol/eq.) in anhydrous THF, an appropriate phosphorochloridate (3.0 mol/eq.) dissolved in anhydrous THF was added dropwise under an argon atmosphere. To that reaction mixture NMI (5.0 mol/eq.) was added dropwise over 5 minutes at -78°C under an argon atmosphere. After 15 minutes, the reaction mixture was let to rise to room temperature and stirred overnight (M + Na + ); Reverse-phase HPLC, eluting with H2O/AcCN from 100/0 to 0/100 in 35 min, F = 1 mL/min,  = 254, two peaks for two diastereoisomers with tR = 14.68, 14.95 min.
5-Fluoro-6-azidouridine-5'-O-[phenyl-(hexoxy-L-alaninyl)] phosphate (29).
Prepared according to the general procedure from 5-fluoro-6-azidouridine 6 (0. 
5-Fluoro-6-methyluridine-5'-O-[phenyl-(benzoxy-L-alaninyl)] phosphate (34).
Prepared according to the general procedure from 5-fluoro-6-methyluridine 7 (0.15 g, 
